Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE:002907)
China · Delayed Price · Currency is CNY 13.64
-0.94 (-6.45%)
Sep 10, 2026, 12:44 PM CST
SHE:002907 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 6,089 | 6,185 | 5,429 | 6,452 | 8,502 | 7,250 | |
Market Cap Growth | -15.13% | 13.92% | -15.86% | -24.12% | 17.27% | 34.50% |
Enterprise Value | 5,453 | 5,651 | 4,957 | 5,999 | 8,261 | 6,982 |
Last Close Price | 14.58 | 14.73 | 12.87 | 15.19 | 19.93 | 17.60 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 82.13 | 95.02 | 70.75 | 197.31 | 86.41 | 79.00 |
PS Ratio | 7.62 | 7.48 | 7.01 | 9.33 | 10.83 | 8.57 |
PB Ratio | 3.49 | 3.62 | 3.27 | 3.99 | 5.28 | 5.73 |
P/TBV Ratio | 3.95 | 4.17 | 3.54 | 4.27 | 5.54 | 6.10 |
P/FCF Ratio | 100.55 | 129.70 | 37.28 | 50.99 | - | 276.62 |
P/OCF Ratio | 68.12 | 99.37 | 33.56 | 29.42 | 651.77 | 87.51 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 6.83 | 6.83 | 6.40 | 8.67 | 10.52 | 8.25 |
EV/EBITDA Ratio | 37.17 | 40.80 | 33.55 | 54.69 | 47.99 | 42.39 |
EV/EBIT Ratio | 97.13 | 107.03 | 81.39 | 215.92 | 84.65 | 73.53 |
EV/FCF Ratio | 90.05 | 118.52 | 34.04 | 47.41 | - | 266.38 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.00 | 0.00 | 0 | 0 | 0 | 0.20 |
Debt / EBITDA Ratio | 0.02 | 0.03 | 0.00 | 0.00 | 0.00 | 1.52 |
Debt / FCF Ratio | 0.06 | 0.08 | 0.00 | 0.00 | - | 9.58 |
Net Debt / Equity Ratio | -0.37 | -0.36 | -0.37 | -0.30 | -0.31 | -0.20 |
Net Debt / EBITDA Ratio | -4.42 | -4.49 | -4.11 | -4.44 | -2.92 | -1.57 |
Net Debt / FCF Ratio | -10.64 | -13.04 | -4.17 | -3.85 | 10.58 | -9.90 |
Asset Turnover | 0.39 | 0.42 | 0.41 | 0.37 | 0.43 | 0.48 |
Inventory Turnover | 2.82 | 2.54 | 2.28 | 2.35 | 2.65 | 3.26 |
Quick Ratio | 3.96 | 3.47 | 4.17 | 3.91 | 3.92 | 3.64 |
Current Ratio | 4.65 | 4.27 | 4.86 | 4.74 | 4.53 | 4.32 |
Return on Equity (ROE) | 3.41% | 3.28% | 4.68% | 2.03% | 6.84% | 7.50% |
Return on Assets (ROA) | 1.72% | 1.67% | 2.02% | 0.93% | 3.35% | 3.40% |
Return on Invested Capital (ROIC) | 3.56% | 3.52% | 4.58% | 1.90% | 8.39% | 8.85% |
Return on Capital Employed (ROCE) | 3.10% | 3.00% | 3.60% | 1.70% | 5.90% | 6.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.22% | 1.05% | 1.41% | 0.51% | 1.16% | 1.27% |
FCF Yield | 0.99% | 0.77% | 2.68% | 1.96% | -0.56% | 0.36% |
Dividend Yield | 0.52% | 0.51% | 0.66% | 0.33% | 0.35% | 0.28% |
Payout Ratio | 42.26% | 54.54% | 46.26% | 92.25% | 23.42% | 14.60% |
Buyback Yield / Dilution | 0.05% | 0.05% | -0.02% | -3.60% | -0.49% | -0.06% |
Total Shareholder Return | 0.57% | 0.56% | 0.64% | -3.27% | -0.14% | 0.22% |